Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy
- 8 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in JBIC Journal of Biological Inorganic Chemistry
- Vol. 26 (4), 467-478
- https://doi.org/10.1007/s00775-021-01863-x
Abstract
The blood–brain barrier (BBB) permeability of molecules needs to meet stringent requirements of Lipinski’s rule, which pose a difficulty for the rational design of efficient chelating agents for Parkinson's disease chelation therapy. Therefore, the iron chelators employed N-aliphatic alcohols modification of deferiprone were reasonably designed in this work. The chelators not only meet Lipinski’s rule for BBB permeability, but also ensure the iron affinity. The results of solution thermodynamics demonstrated that the pFe3+ value of N-hydroxyalkyl substituted deferiprone is between 19.20 and 19.36, which is comparable to that of clinical deferiprone. The results of 2,2-diphenyl-1-picrylhydrazyl radical scavenging assays indicated that the N-hydroxyalkyl substituted deferiprone also possesses similar radical scavenging ability in comparison to deferiprone. Meanwhile, the Cell Counting Kit-8 assays of neuron-like rat pheochromocytoma cell-line demonstrated that the N-hydroxyalkyl substituted deferiprone exhibits extremely low cytotoxicity and excellent H2O2-induced oxidative stress protection effect. These results indicated that N-hydroxyalkyl substituted deferiprone has potential application prospects as chelating agents for Parkinson's disease chelation therapy strategy. Graphic abstractKeywords
Funding Information
- Independent Research Projects of State Key Laboratory of Environment-friendly Energy Materials (19fksy04)
This publication has 47 references indexed in Scilit:
- A novel fluorescence method for determination of pFe3+The Analyst, 2013
- Actinide chelation: biodistribution andin vivocomplex stability of the targeted metal ionsToxicology Mechanisms and Methods, 2012
- Chelation therapy for neurodegenerative diseasesMedicinal Research Reviews, 2009
- Potentiometric, spectrophotometric and calorimetric study on iron(III) and copper(II) complexes with 1,2-dimethyl-3-hydroxy-4-pyridinoneJournal of Inorganic Biochemistry, 2008
- Blood–brain barrier deliveryDrug Discovery Today, 2007
- Iron, brain ageing and neurodegenerative disordersNature Reviews Neuroscience, 2004
- A selectivity model for fragmented relations: applied in information retrievalIEEE Transactions on Knowledge and Data Engineering, 2004
- Neurodegenerative diseases and oxidative stressNature Reviews Drug Discovery, 2004
- The stability of the metal complexes of cyclic tetra-aza tetra-acetic acidsTalanta, 1992
- Computer simulation of metal ion equilibria in biofluids. IV. plutonium speciation in human blood plasma and chelation therapy using polyaminopolycarboxylic acidsJournal of Inorganic Biochemistry, 1984